Recorlev was the largest of Xeris Biopharma Holdings, Inc.’s 5 reported lines in fiscal 2025, at $139.28M — 48% of $291.85M.
| Product and Service | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|
| Gvoke | $52.53M | $67.05M | $82.83M | $94.11M | |
| Recorlev | $7.43M | $29.55M | $64.28M | $139.28M | |
| Keveyis | $49.31M | $56.77M | $49.53M | $47.65M | |
| Royalty, Contract & Other Revenue | $985.00K | $10.55M | $6.43M | $8.84M | |
| Other Product Revenue | — | — | — | $1.96M | |
| Total | $110.25M | $163.91M | $203.07M | $291.85M |
In fiscal 2025, which ended December 31, 2025, the 5 revenue lines Xeris Biopharma Holdings, Inc. reported in this breakdown added up to $291.85M. The revenue lines reported changed from fiscal 2024, so the total is not directly comparable with the $203.07M reported that year. Recorlev was the largest revenue line, at $139.28M or 47.7% of the total, followed by Gvoke ($94.11M, 32.2%) and Keveyis ($47.65M, 16.3%). Together, the two largest revenue lines made up 80.0% of this total.
Compared with fiscal 2024, Recorlev grew the fastest, rising 116.7% to $139.28M. Keveyis fell the most, down 3.8% to $47.65M. Because revenue lines were added or dropped between the two years, part of this reflects how Xeris Biopharma Holdings, Inc. regrouped its reporting.
Other Product Revenue was first reported as a separate revenue line in fiscal 2025. This breakdown covers every fiscal year from 2021 to 2025, as reported in Xeris Biopharma Holdings, Inc.'s annual filings.
Xeris Biopharma Holdings, Inc. (XERS) breaks its revenue down by revenue line. In fiscal 2025, its largest revenue line was Recorlev, with $139.28M or 47.7% of the total, followed by Gvoke at $94.11M (32.2%).
Recorlev was Xeris Biopharma Holdings, Inc.'s largest revenue line in fiscal 2025, with $139.28M in revenue, 47.7% of the $291.85M reported across its 5 revenue lines.
Every figure is taken from Xeris Biopharma Holdings, Inc.'s annual financial filings and shown as reported: each line keeps the name the company gives it, years follow its own fiscal calendar, and lines it has stopped reporting stay in the table for the years they were reported.
The breakdown by revenue line covers fiscal 2021 to 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.